Neumora Therapeutics (NASDAQ:NMRA) Price Target Cut to $20.0

Neumora Therapeutics (NASDAQ:NMRA – Free Report) had its price target reduced by JPMorgan Chase & Co. from $21.00 to $20.00 in a report released on Wednesday morning, Benzinga reports. They currently have an overweight rating on the stock. Other research analysts have also recently issued reports about the stock. William Blair assumed coverage on shares […]

Related Keywords

United States , Canada , America , William Blair , Stifel Nicolaus , Kristina Burow , Jpmorgan Chase Co , Neumora Therapeutics Inc , Neumora Therapeutics Company Profile , Royal Bank , Wellcome , Securities Exchange Commission , Arch Venture Partners Xii Llc , Nasdaq , Neumora Therapeutics , Free Report , Therapeutics Trading Down , Get Free Report , Arch Venture Partners Xii , Director Kristina Burow , Neumora Therapeutics Daily , Nasdaq Nmra , Nmra , Medical , Lower Price Target ,